What Синкейро Treats: Main Uses and Benefits

This treatment is an add-on therapy specifically for adults with severe, chronic asthma that is characterized by an elevated blood eosinophil count (eosinophilic phenotype). It is applied when conditions are not adequately controlled despite optimized standard maintenance medications. This therapeutic approach is relevant for managing symptoms that are linked to organ-specific functional stress and supports long-term disease management.

It is used for managing severe asthma exacerbations and assisting with oral corticosteroid reduction in this patient group.

“This supportive relief can help ease challenging manifestations like persistent wheezing and shortness of breath.”

Quick Fact: Relief for Severe Symptoms

Area of Support	Benefit
Asthma Severity	Supports the management of conditions presenting with systemic or localized discomfort.
Exacerbations	Is relevant for managing symptoms that become more disruptive during flare-ups.
Functional Capacity	Supports maintaining functional stability.
Systemic Burden	Assists with reducing the overall symptom burden.

Eligibility Map: Who Can and Cannot Use Синкейро (Reslizumab) — Official Regulatory Information

Eligibility scope	Category	Official Regulatory Statement (Strictly Eligibility)
Populations for whom use is allowed (as stated in label)	Adults aged 18 years and older with severe asthma who have an eosinophilic phenotype.
Populations for whom use is not recommended (if applicable)	Pregnant patients and lactating patients, due to insufficient data on drug-associated risk or excretion into human milk, respectively.
Populations for whom use is contraindicated	Patients with known hypersensitivity to reslizumab or any of its excipients.
Age-related eligibility rules	The minimum age is 18 years. Safety and effectiveness have not been established in pediatric patients. No dose adjustment is needed for geriatric patients.
Condition-specific eligibility rules	Renal/Hepatic Impairment: No dose adjustment is required, but use has not been studied in severe renal impairment.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Data is insufficient to inform drug-associated risk. Lactation: It is unknown if the medicine is excreted in human milk.
Eligibility-related restrictions	Not indicated for the relief of acute bronchospasm or status asthmaticus. Patients with pre-existing helminth (parasitic) infections must be treated prior to therapy initiation.

---

Eligibility classifications (high-level)	Classification	Official Regulatory Wording (Directly from Labeling)
Eligibility severity classification (as defined in official documents)	Contraindicated (for hypersensitivity); Not Indicated (for acute conditions and pediatric patients).
Regulatory basis (EMA / FDA / etc.)	FDA Full Prescribing Information, EMA Summary of Product Characteristics.
Eligibility-context constraints (as defined in official documents)	Use is limited to add-on maintenance treatment in a specific phenotype.

---

Resulting eligibility structure Official eligibility statements:

• The medicine is contraindicated in patients with a known hypersensitivity to reslizumab.
• The drug is not indicated for use in patients younger than 18 years of age.
• The drug is not indicated for the relief of acute bronchospasm or status asthmaticus.
• Patients with pre-existing helminth infections must be treated before initiating therapy.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents strictly define the eligible patient group as adults aged 18 and older with severe eosinophilic asthma. Eligibility is restricted by an absolute contraindication for hypersensitivity, and the medicine is explicitly not indicated for pediatric use or the treatment of acute asthma crises. Use is conditional on treating pre-existing parasitic infections, although no dosage adjustment is required for renal or hepatic impairment.

Pharmacokinetic Interaction Status

Official regulatory documentation states that Reslizumab, as a large monoclonal antibody, is cleared through natural catabolic processes and is not expected to affect the activity of major drug-metabolizing enzymes, such as CYP1A2 or CYP3A4. Population pharmacokinetic analyses confirm that the co-administration of commonly used asthma maintenance treatments, including leukotriene antagonists and systemic corticosteroids, does not result in a clinically significant change in Reslizumab exposure.

Administration and Co-use Restrictions

Due to a lack of physical or biochemical compatibility data, Reslizumab must be administered through a dedicated intravenous line and is strictly prohibited from being co-infused with any other medicinal product. The safety and efficacy of co-use have not been established with live vaccines or immunosuppressant medicinal products other than oral corticosteroids.

Condition-Specific Constraints

Regulatory labeling places two key constraints related to co-administration. First, patients with a pre-existing helminth (parasitic) infection must be treated before initiating therapy; temporary discontinuation of Reslizumab should be considered if the infection is acquired and does not resolve. Second, patients must not abruptly discontinue their existing systemic or inhaled corticosteroid medications upon starting treatment.

Targeted Neutralization of Interleukin-5 (IL-5)

The drug acts as a specialized antagonist by binding with high affinity to the soluble Interleukin-5 (IL-5) protein, a cytokine involved in the mediation of eosinophil-driven inflammatory responses. This molecular action immediately neutralizes the cytokine, effectively preventing the necessary communication required for the growth and activation of target inflammatory cells.

Suppression of Eosinophil Survival and Maturation

By blocking the IL-5 signal, the drug disrupts the signaling pathway that supports eosinophil survival and maturation. This action accelerates the natural programmed death (apoptosis) of circulating eosinophils and suppresses the maturation of new cells in the bone marrow. This mechanism causes a reduction in the count of circulating eosinophils.

Functional Modulation of the T2 Inflammatory Axis

The systemic reduction of the core effector cell, the eosinophil, limits the release of pro-inflammatory mediators into the airways. This action provides a highly specific functional modulation of the T-helper type 2 (Th2) inflammatory pathway, which results in the dampening of specific inflammatory processes where they are driven by this particular biological axis.

Instruction Map: How to use Синкейро — Administration Guidelines

The following administration guidelines describe the requirements for the proper use of Reslizumab (Синкейро).

---

Administration Scope

Requirement	Detail
Route of administration	The medicine is restricted to Intravenous (IV) Infusion only. Administration by methods such as IV push or bolus is specifically restricted.
Dosing schedule	The standardized regimen is a weight-based dose of 3 mg/kg (milligrams per kilogram) of the patient's body weight.
Timing in relation to meals (if applicable)	Not applicable.
Preparation requirements (if applicable)	The concentrate must be diluted into 50 mL of 0.9% Sodium Chloride solution prior to infusion; the concentrate vial and final solution must not be shaken.
Age-group administration rules	Approved for adult patients (18 years of age and older). No dose adjustment is required for older adults or individuals with renal impairment.
Missed-dose rules	If a scheduled dose is missed, dosing should resume as soon as possible; a double dose must not be administered.
Special procedural conditions	Infusion must be delivered over a period of 20 to 50 minutes using an in-line 0.2 micron filter. The procedure must occur in a specialized healthcare setting.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Intravenous (IV).
Frequency pattern	Fixed cyclic, administered once every four weeks.
Basis of use	Standardized prescribing information.
Use-context constraints	Professional healthcare setting; mandatory technical preparation and delivery procedures.

---

Resulting Procedural Structure

Step sequence:

• The required volume of concentrate is calculated and diluted into the 50 mL saline bag.
• The prepared solution is then delivered via slow, continuous intravenous infusion.
• The infusion is monitored over its 20 to 50 minute duration using an in-line filter.
• The procedure is repeated every four weeks for long-term maintenance.

Connection to the Overall Use Protocol

The use protocol is dictated by technical administration requirements, ensuring the correct, weight-based dose is delivered directly into the bloodstream under professional observation. The fixed 4-week schedule and the requirement for an annual reassessment of continuation define the necessary long-term maintenance regimen.

Core Research for Severe Eosinophilic Asthma

The primary evidence base involves multiple, 52-week Randomized Controlled Trials (RCTs) applied in research settings examining this medicine as an add-on maintenance treatment for adults with severe asthma characterized by high eosinophil counts. Adult patients were randomly assigned to receive either the medicine or a placebo. These studies explored how the frequency of episodic changes, known as asthma flare-ups or exacerbations, varied between the groups. Researchers also monitored objective measures of functional imbalance, such as changes in lung function (Forced Expiratory Volume in 1 second, or FEV1), and tracked patient-reported experiences of asthma control. The trials reported data on the rate of severe flare-ups and monitored measured outcomes related to lung function and perceived discomfort over the one-year observation period.

---

Research on Oral Corticosteroid Sparing

Research was conducted exploring the possibility of reducing the required dose of oral corticosteroids (OCS) in OCS-dependent patients. The studies primarily relied on post-hoc analyses of the main trial data, examining changes in the total systemic corticosteroid (SCS) burden. Studies monitored the use of OCS in this specific patient subgroup during the 52-week trial period. It is noted that no dedicated, prospective clinical trial was conducted specifically to test OCS dose reduction as a primary endpoint, meaning this evidence is derived mostly from secondary research.

---

Limitations and Research Gaps

The long-term effects are not fully established because the core evidence is limited to the one-year duration of the pivotal RCTs. Data for certain groups remain insufficient, including evidence for adolescents (age 12–17) and certain non-Caucasian populations, as their sample sizes were modest. Comparative evidence is lacking to directly assess this medicine against other biologic treatments in the same class. Research provides context but not individual predictions, and studies help show what has been observed so far under the specific conditions of the trials.

Common questions about Синкейро (FAQ)

Q: Is Синкейро a hormonal drug or not?

Official product information states that Синкейро (Reslizumab) is a biological medicine classified as a monoclonal antibody, specifically an anti-interleukin-5 antagonist. It works by targeting a specific protein involved in inflammation. Therefore, it is not categorized as a steroid or hormonal medication.

---

Q: Can Синкейро cause severe fatigue or drowsiness?

Severe fatigue or strong drowsiness are not listed among the commonly reported side effects in the official regulatory documents. If any unusual weakness or sleepiness is experienced during treatment, consulting with the prescribing healthcare professional is recommended.

---

Q: Can I use Синкейро if I am already taking other medications for a similar condition?

Regulatory analyses show that Reslizumab, being a large monoclonal antibody, is cleared through natural processes and is not expected to interfere with drug-metabolizing enzymes. Study data indicates that co-administration with standard asthma maintenance treatments, including inhaled corticosteroids, did not result in a clinically significant change in Reslizumab exposure.

---

Q: Can people with kidney or liver problems take Синкейро?

Official information indicates that no dose adjustment is generally required for patients with mild to moderate kidney or liver impairment. However, the use of Reslizumab has not been specifically studied in individuals with severe renal impairment.

---

Q: What information is available regarding the use of Синкейро in children?

Синкейро is officially indicated for use only in adults aged 18 years and older. Safety and effectiveness in the pediatric population have not been established by regulatory authorities.

---

Q: Where can I find the official instructions for using Синкейро?

Official regulatory documents, such as the FDA's Full Prescribing Information or the EMA's Summary of Product Characteristics (SmPC), are publicly available on the respective government regulator websites. The Patient Information Leaflet is included in the product packaging, and additional clarification can be sought from the administering healthcare provider.

---

Q: What kind of sensations might occur at the injection site for Синкейро?

Синкейро is administered strictly via slow intravenous (IV) infusion into a vein, not as a subcutaneous injection (a shot under the skin). Because it is administered intravenously, the local site reactions commonly associated with subcutaneous or intramuscular injections are generally not applicable.

---

Q: Is it true that Синкейро can cause headache or dizziness?

Headache and dizziness are not listed among the most common adverse reactions reported in clinical trials. However, dizziness or nausea may sometimes be signs of infusion-related reactions, and, according to official warnings, require medical supervision during or after the procedure.

---

Q: What ingredients does Синкейро contain besides the main active substance?

In addition to the active substance Reslizumab, official labeling specifies the product contains excipients (inactive ingredients). These include sodium acetate trihydrate, acetic acid, trehalose dihydrate, and water for injection.

---

Q: Does the treatment regimen for Синкейро change based on the patient's age?

The treatment is based on the patient's body weight, meaning the total dose will vary accordingly. Official product information indicates that no dose adjustment is required specifically based on age for adult patients.

---

Q: Can Синкейро cause dry mouth or other mucosal problems?

The most frequently reported common side effect observed in clinical studies was oropharyngeal pain, which is pain in the throat or back of the mouth.

---

Q: What precautions should be taken if self-administering Синкейро?

Official regulatory documents indicate that Синкейро is restricted to administration by a trained healthcare professional in a clinical setting. This procedure ensures proper dilution and delivery, as well as access to equipment necessary to manage potential severe allergic reactions.

---

Q: Does Синкейро affect the possibility of conception (fertility)?

Non-clinical studies conducted on animals showed no evidence that the medicine affects the reproductive function in either males or females. However, official regulatory information notes that data regarding the effect of the medication on human fertility is currently unavailable.

The storage and disposal of CINQAIR (reslizumab) must strictly follow official regulatory guidelines to maintain product integrity.

Storage Component	Regulatory Requirement
Unopened Vials	Must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F). Do not freeze or shake the vial, and keep it in the original carton to protect from light.
Diluted Solution	After preparation, the solution is stable for a total of 16 hours at either refrigerator temperatures (2 C to 8 C) or at room temperature (up to 25 C or 77 F), but must be protected from light.
Handling Check	The solution must be visually inspected for particulate matter and discoloration prior to preparation.
Child Safety	The medicine must be kept out of the sight and reach of children.

For disposal, CINQAIR is supplied in single-use vials, and any unused portion remaining after dose withdrawal must be discarded. Expired or unneeded product should not be disposed of in household trash or wastewater, but must be handled according to local waste regulations.